Physician Assistant · Delran, NJ
NPI
1922100130
Since 2006
Specialty
Physician Assistant
Code 363A00000X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
8001 Route 130
Delran, NJ, 08075
Phone (856) 461-1400
Groups this clinician bills Medicare through
Medicare paid, 2024
$70K
1,498 services
Medicare patients, 2024
467
Average age 74
Drug cost, 2024
$973K
675 prescriptions
Company payments, 2025
$784
From 12 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Jennifer A Rosborough was code 99213 (office e&m - established), 337 times for 281 patients. In total Jennifer A Rosborough billed 1,498 services in 59 codes, and Medicare paid $70K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2007-07-08.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99213 Office E&M - Established | Office | 337 | 281 | $50.97 | $17K |
| 17003 Destruction Skin Lesion | Office | 305 | 93 | $4.32 | $1,317 |
| 17000 Destruction Skin Lesion | Office | 207 | 157 | $35.27 | $7,301 |
| 99214 Office E&M - Established | Office | 129 | 104 | $76.76 | $9,902 |
| 11102 Skin Biopsy | Office | 87 | 79 | $57.62 | $5,013 |
| 17110 Destruction Skin Lesion | Office | 71 | 63 | $58.58 | $4,159 |
| 99212 Office E&M - Established | Office | 49 | 47 | $31.49 | $1,543 |
| J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 37 | 16 | $0.60 | $22.21 |
| 99203 Office E&M - New | Office | 37 | 37 | $53.91 | $1,995 |
| 11900 Skin | Office | 18 | 14 | $27.67 | $498 |
| 12031 Wound Repair - All Levels | Office | 15 | 15 | $190.61 | $2,859 |
| 99202 Office E&M - New | Office | 15 | 15 | $34.57 | $519 |
| 11103 Skin Biopsy | Office | 14 | 11 | $33.87 | $474 |
| 17261 Destruction Skin Lesion | Office | 13 | 12 | $91.31 | $1,187 |
By year: 2022 $57K for 1,256 services; 2023 $68K for 1,517 services; 2024 $70K for 1,498 services.
Medicare prescription drug claims, 2024
In 2024, the drug Jennifer A Rosborough prescribed most often to Medicare patients was Ketoconazole, with 101 prescriptions and refills. In total Jennifer A Rosborough wrote 675 Medicare prescriptions that cost $973K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ketoconazole Generic | 101 | 111 | 43 | $1,713 |
| Triamcinolone Acetonide Generic | 70 | 80 | 48 | $714 |
| Fluorouracil Generic | 47 | 51 | 44 | $3,311 |
| Clobetasol Propionate Generic | 33 | 39 | 24 | $1,671 |
| Metronidazole Generic | 29 | 32 | 16 | $1,105 |
| Dupixent Syringe Dupilumab | 26 | 30 | Under 11 | $113K |
| Taltz Autoinjector Ixekizumab | 20 | 20 | Under 11 | $133K |
| Otezla Apremilast | 19 | 21 | Under 11 | $100K |
| Doxycycline Hyclate Generic | 19 | 39 | Under 11 | $711 |
| Mometasone Furoate Generic | 15 | 15 | 11 | $238 |
| Prednisone Generic | 15 | 15 | Under 11 | $10.44 |
| Enbrel Sureclick Etanercept | 14 | 14 | Under 11 | $101K |
| Xolair Omalizumab | 14 | 18 | Under 11 | $39K |
| Enbrel Etanercept | 13 | 13 | Under 11 | $96K |
| Imiquimod Generic | 13 | 19 | Under 11 | $756 |
Brand drugs: 201 claims; generic drugs: 474 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Jennifer A Rosborough $784 ($784 in general payments such as food, travel and fees) from 12 companies. The largest payer was Abbvie Inc. with $210.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 16 | $210 |
| Novartis Pharmaceuticals Corporation NVS | 13 | $181 |
| LEO Pharma Inc. | 5 | $76.96 |
| Janssen Biotech, Inc. JNJ | 4 | $68.99 |
| Incyte Corporation INCY | 3 | $46.37 |
| Lilly USA, LLC LLY | 3 | $45.24 |
| UCB, Inc. UCB.BR | 2 | $35.33 |
| E.R. Squibb & Sons, L.L.C. BMY | 2 | $33.77 |
| Sun Pharmaceutical Industries Inc. SUNPHARMA.NS | 2 | $32.5 |
| Organon LLC OGN | 2 | $18.65 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.